Safety monitoring of atorvastatin combined with hybomib in the treatment of hyperlipidemia: a multicentre, hospital-focused monitoring study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400092594

Enrollment

Unknown

Registered

2024-11-19

Start date

2024-11-20

Completion date

Unknown

Last updated

2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia

Interventions

Monitoring group:Atorvastatin combination with hybomeib

Eligibility

Sex/Gender

All

Age

No minimum to 100 Years

Inclusion criteria

Inclusion criteria: 1. Confirm the diagnosis of hyperlipidemia 2. Patients receiving atorvastatin combined with hybomaib 3. The patient's gender, age and underlying disease are not limited 4. Duration of drug use, drug specifications, and combination of drugs are not limited

Exclusion criteria

Exclusion criteria: Patients whose information was not available for this study

Design outcomes

Primary

Measure	Time frame
Incidence of adverse reactions;Severity of adverse reactions;Type of adverse reaction;	—

Countries

China

Contacts

Public ContactLi Zhengxiang

Tianjin Medical University General Hospital

13820893896@163.com+86 138 2089 3896

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026